C75 (FASN Inhibitor)
Product Code:
AG-CR1-2904
AG-CR1-2904
Regulatory Status:
RUO
RUO
Target Species:
Universal
Universal
Shipping:
AMBIENT
AMBIENT
Storage:
-20°C
-20°C
No additional charges, what you see is what you pay! *
| Code | Size | Price |
|---|
| AG-CR1-2904-M001 | 1 mg | £60.00 |
Quantity:
| AG-CR1-2904-M005 | 5 mg | £160.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Related Products
- Show All
Further Information
Alternate Names/Synonyms:
(?)-C75; 4-Methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid
Appearance:
White to off-white solid.
CAS:
191282-48-1
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.Protect from light.
InChi:
InChI=1S/C14H22O4/c1-3-4-5-6-7-8-9-11-12(13(15)16)10(2)14(17)18-11/h11-12H,2-9H2,1H3,(H,15,16)
InChiKey:
VCWLZDVWHQVAJU-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 191282-48-1. Formula: C14H22O4. MW: 254.3. . Stable synthetic cerulenin derivative. Competitive irreversible fatty acid synthase (FASN) inhibitor that acts on KR, ACP and TE domains. Used to study fatty acid synthesis in metabolic disorders and cancer. Useful agent for immunometabolism research. Anorexigenic agent, activating CPT1 to accelerate fatty acid beta-oxidation. Shown to inhibit food intake through AMPK-related pathways. Cytotoxic to many cancer cell lines. Antitumor agent shown to suppress DNA replication and induce apoptosis.
MDL:
MFCD03426157
Molecular Formula:
C14H22O4
Molecular Weight:
254.3
Package Type:
Vial
Product Description:
Stable synthetic cerulenin derivative. Competitive irreversible fatty acid synthase (FASN) inhibitor that acts on ketoreductase (KR), acyl carrier protein (ACP) and thioesterase (TE) domains. Used to study fatty acid synthesis in metabolic disorders and cancer. Useful agent for immunometabolism research. Anorexigenic agent, activating CPT1 to accelerate fatty acid beta-oxidation. Shown to inhibit food intake through AMPK-related pathways. Cytotoxic to many cancer cell lines. Antitumor agent shown to suppress DNA replication and induce apoptosis. Specifically blocks TLR/MYD88 signaling in neutrophils.
Purity:
>98%
SMILES:
O=C(OC(CCCCCCCC)C1C(O)=O)C1=C
Solubility Chemicals:
Soluble in DMSO (10mg/ml), DMF or ethanol (both 20mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
Documents
References
Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines: E.S. Pizer, et al.; Cancer Res. 58, 4611 (1998) | Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors: T.M. Loftus, et al.; Science 288, 2379 (2000) | Synthesis and antitumor activity of an inhibitor of fatty acid synthase: F.P. Kuhajda, et al.; PNAS 97, 3450 (2000) | Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides: T. Shimokawa, et al.; PNAS 99, 66 (2002) | C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity: J.N. Thupari, et al.; PNAS 99, 9498 (2002) | The anorexigenic fatty acid synthase inhibitor, C75, is a nonspecific neuronal activator: K.A. Takahashi, et al.; Endocrinol. 145, 184 (2004) | Long-term effects of a fatty acid synthase inhibitor on obese mice: food intake, hypothalamic neuropeptides, and UCP3: S.H. Cha, et al.; BBRC 317, 301 (2004) | C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism: L.E. Landree, et al.; J. Biol. Chem. 279, 3817 (2004) | A guide to immunometabolism for immunologists: L.A. O'Neill, et al.; Nat. Rev. Immunol. 16, 553 (2016) | Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors: G. Andrejeva & J.C. Rathmell; Cell Metab. 26, 49 (2017) | Metabolic Instruction of Immunity: M.D. Buck, et al.; Cell 169, 570 (2017) | Toll-like receptor mediated inflammation requires FASN-dependent MYD88 palmitoylation: YC. Kim, et al.; Nat. Chem. Biol. 15, 907 (2019) | Rewiring of Lipid Metabolism and Storage in Ovarian Cancer Cells after Anti-VEGF Therapy: M. Curtarello, et al.; Cells 8, 1601 (2019)